In critically ill patients, standard-dose (40 mg) enoxaparin may yield subtherapeutic levels of anti-factor Xa [36], likely secondary to impaired absorption from vasopressor-mediated vasoconstriction, subcutaneous edema, and obesity. This evidence concerns the gene F10 and obesity disorder.